Pharmaceutical Interventions for the Management of No-Reflow

Tim A. Fischell, MD

J Invasive Cardiol. 2008;20(7):374-379. 

In This Article

Glycoprotein IIb/IIIa Inhibitors

Interference with platelet aggregation through glycoprotein (GP) IIb/IIIa receptor inhibition is a theoretically attractive method for management of no-reflow that awaits confirmation by randomized study. Tirofiban reduced no-reflow in a canine non-thrombotic coronary occlusion model, and was more effective than aspirin or clopidogrel in attenuating no-reflow in a swine infarction/reperfusion model, but reports in human subjects are scant and inconclusive.[37,38,39]

Clinical reports suggest that abciximab improves epicardial flow and microvascular perfusion as an adjunct to reduced-dose thrombolysis[40] and after primary PCI.[41] In a subset of 101 patients with SVGs undergoing high-risk PCI, adjunctive abciximab bolus and infusion were associated with an 87% reduction in distal embolization compared with placebo (2% vs. 18%, p = 0.017), with a trend toward reduction in early large non-Q-wave AMI (2% vs .12%, p = 0.165).[42]

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....